Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07142954 · ClinicalTrials.gov registry record · Phase 3
Epidemiology and Biomarker Study in Alzheimer's Disease
A Phase 3 study of Alzheimer Disease, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 3,400
- Enrollment target
- 3
- Study locations
NCT07142954 is a Phase 3 study of Alzheimer Disease that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 3,400 participants, above the 2,740-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (24% higher). The trial reports 3 study locations across 2 states.
The verdict
NCT07142954, a Phase 3 study of Alzheimer Disease, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 3,400 participants
- Enrollment target
- 3
- Study locations
Study Summary
Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.
Conditions Studied
Interventions
- OTHER P-tau217 Test
Study Locations (3)
Other
- The University of Tokyo Hospital - Bunkyō City
- Souseikai Sumida Hospital - Tokyo
Texas
- Care Access - Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,400 participants |
| Start Date | 2025-08-25 |
| Est. Completion | 2033-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07142954
The ClinicalTrials.gov registry entry for NCT07142954 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 3,400 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,740-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (24% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which P-tau217 Test is the first listed.
NCT07142954 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Other, Texas.
Frequently Asked Questions
What is clinical trial NCT07142954 about?
NCT07142954 is a clinical study titled "Epidemiology and Biomarker Study in Alzheimer's Disease". Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.
What is the current status of trial NCT07142954?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 3,400 participants. The study started on 2025-08-25. Estimated completion is 2033-07.
What conditions does trial NCT07142954 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT07142954?
The interventions under investigation include: P-tau217 Test (OTHER).
Who is sponsoring clinical trial NCT07142954?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07142954 being conducted?
This trial has 3 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Biomarker Exploration in Aging, Cognition and Neurodegeneration
RECRUITING · Phase 3
-
[18F]PI-2620 Phase 3 Histopathological Study
RECRUITING · Phase 3
-
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
RECRUITING · Phase 3
-
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
RECRUITING · Phase 3
-
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.